Zoetis Announces Second Quarter 2024 Results

Rhea-AI Summary

Zoetis Inc. (NYSE:ZTS) reported strong Q2 2024 results, with revenue of $2.4 billion, up 8% (11% operational growth). Net income was $624 million ($1.37 per diluted share), down 7% and 6% respectively. Adjusted net income reached $711 million ($1.56 per diluted share), up 9% and 11% on a reported basis, and 18% and 20% operationally.

The company saw impressive growth in both U.S. (12%) and International (10% operational) segments, with strong performance in companion animal and livestock portfolios. Key drivers included osteoarthritis pain products, Simparica Trio, and dermatology offerings.

Zoetis raised its full-year 2024 guidance, projecting revenue between $9.100-$9.250 billion (9-11% operational growth) and adjusted diluted EPS of $5.78-$5.88.

Positive

• Revenue increased by 8% (11% operational growth) to $2.4 billion in Q2 2024
• Adjusted net income grew by 18% operationally to $711 million
• U.S. segment revenue increased by 12%, with companion animal products up 13%
• International segment revenue grew 10% operationally
• Full-year 2024 guidance raised, projecting 9-11% operational revenue growth

Negative

• Reported net income decreased by 7% to $624 million in Q2 2024
• Reported diluted EPS declined by 6% to $1.37 per share

Insights

Financial Analyst

Zoetis' Q2 2024 results demonstrate strong performance, with revenue up 8% to $2.4 billion and operational revenue growth of 11%. The company's adjusted net income grew by 18% operationally, showing robust profitability. Key growth drivers include the U.S. segment (12% increase) and international operational growth (10%).

The raised full-year guidance, projecting operational revenue growth of 9% to 11% and operational adjusted net income growth of 13.5% to 15.5%, indicates management's confidence in continued strong performance. This upward revision is particularly noteworthy given the current economic climate, suggesting Zoetis' resilience and strong market position in animal health.

Investors should note the impressive growth in companion animal products, especially in osteoarthritis pain treatments and parasiticides, which highlights Zoetis' successful innovation strategy. The planned launch of the Vetscan® Opticell™ diagnostic analyzer further reinforces the company's commitment to expanding its product portfolio.

Market Research Analyst

Zoetis' Q2 results reveal significant market penetration and expansion. The 12% operational growth in companion animal products globally indicates a thriving pet care market, likely driven by increased pet ownership and spending. The strong performance of products like Librela®, Solensia® and Simparica Trio® suggests successful market positioning and customer adoption.

In the livestock sector, the 8% operational growth internationally, despite challenges, demonstrates Zoetis' ability to capitalize on global agricultural trends. The growth in fish products in Norway highlights the company's adaptability to regional market demands.

The approval of new products across various markets (Canada, Japan, Mexico) showcases Zoetis' global expansion strategy and ability to navigate diverse regulatory environments. This geographical diversification could provide a buffer against regional economic fluctuations, making it an attractive aspect for investors considering long-term stability.

Veterinary Medicine Expert

Zoetis' Q2 results highlight significant advancements in animal health solutions. The strong performance of osteoarthritis pain treatments Librela® and Solensia® indicates a growing focus on chronic disease management in companion animals, addressing an important unmet need in veterinary medicine.

The success of Simparica Trio® and the expanded claim for Simparica® against Asian longhorned ticks in Canada demonstrate the company's commitment to comprehensive parasite control. This is important as vector-borne diseases become more prevalent due to climate change and globalization.

The upcoming launch of Vetscan® Opticell™ represents a significant step in point-of-care diagnostics, potentially improving clinical workflows and patient outcomes. The continued innovation in livestock vaccines, such as Fostera® Gold PCV MH and Alpha Ject Micro® 7 ISA, shows Zoetis' dedication to supporting food security and sustainable animal agriculture.

• Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Quarter 2024

• Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for Second Quarter 2024

• Reports Adjusted Net Income of $711 Million, or Adjusted Diluted EPS of $1.56, for Second Quarter 2024

• Raises Full Year 2024 Revenue Guidance to $9.100 - $9.250 Billion, with Diluted EPS of $5.35 to $5.45 on a Reported Basis, or $5.78 to $5.88 on an Adjusted Basis

• Increases Full Year 2024 Operational Revenue Growth to 9% to 11% and Full-Year Operational Growth in Adjusted Net Income to 13.5% to 15.5%

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2024 and raised its guidance for full year 2024.

The company reported revenue of $2.4 billion for the second quarter of 2024, an increase of 8% compared with the second quarter of 2023. On an operational¹ basis, revenue for the second quarter of 2024 increased 11% compared with the second quarter of 2023. Net income for the second quarter of 2024 was $624 million, or $1.37 per diluted share, a decrease of 7% and 6%, respectively, on a reported basis.

Adjusted net income² for the second quarter of 2024 was $711 million, or $1.56 per diluted share, an increase of 9% and 11%, respectively, on a reported basis, and an increase of 18% and 20%, respectively, on an operational basis. Adjusted net income for the second quarter of 2024 excludes the net impact of $87 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

EXECUTIVE COMMENTARY

“We had another outstanding quarter, demonstrating the strong demand for our trusted, innovative products, our ability to capture and expand markets, and the dedication of our purpose-driven colleagues," said Kristin Peck, Chief Executive Officer of Zoetis. “We achieved 12% revenue growth in the U.S. and 10% operational revenue growth internationally, with both our companion animal and livestock portfolios seeing impressive global operational growth, 12% and 9% respectively."

"Our excellent first half across key franchises, including osteoarthritis (OA) pain, Simparica and key dermatology, is a testament to our commitment to deliver breakthrough innovations that address our customers' unmet needs and our differentiated execution. I look forward to continuing our momentum into the second half of the year where we will remain focused on executing our strategy, building trust and preference for our best-in-class products and delivering value to shareholders.”

QUARTERLY HIGHLIGHTS

Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the second quarter of 2024:

• Revenue in the U.S. segment was $1.3 billion, an increase of 12% compared with the second quarter of 2023. Sales of companion animal products increased 13%, driven by the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela^® for dogs and Solensia^® for cats. Also contributing to growth in the quarter was Simparica Trio^®, the company's flea, tick and heartworm combination product as well as the company's key dermatology portfolio, including Apoquel^® and Cytopoint^®. Sales of livestock products increased 11% in the quarter. Growth in both cattle and swine products was driven primarily by a soft prior year comparison due to the timing of supply of ceftiofur.

• Revenue in the International segment was $1.0 billion, reflecting a 4% increase on a reported basis and an increase of 10% operationally compared with the second quarter of 2023. Sales of companion animal products grew 7% on a reported basis and 12% operationally. Growth in the quarter was driven by the company’s companion animal products, including Simparica^® and Simparica Trio, key dermatology products, Apoquel and Cytopoint, as well as OA pain products, Librela for dogs and Solensia for cats. Sales of livestock products were flat on a reported basis and grew 8% operationally. Growth of the company's cattle and poultry products was driven largely by price increases in hyperinflationary markets. Sales of fish products grew due to increased demand for vaccines in Norway.

INVESTMENTS IN GROWTH

Zoetis continues to advance innovation and care for animals across the globe. Since its last quarterly earnings announcement, the company gained approval in Canada for Alpha Ject Micro^® 7 ISA, the latest version of its combination vaccine for Atlantic Salmon, now enhanced with protection against Infectious Salmon Anaemia Virus (ISA). Simparica and Simparica Trio received approval in Canada for a claim related to the treatment and control of Asian longhorned tick infestations (Haemaphysalis longicornis) in dogs.

The company also received approval in Japan for Draxxin^® KP (tulathromycin ketoprofen), an injectable for the treatment of bacterial pneumoniae in cattle. Fostera^® Gold PCV MH, a one-shot vaccine for pigs that offers the longest lasting combined protection against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae infections, gained approval in Mexico for a claim related to breeding herd safety.

The company is further strengthening its Diagnostic offerings with the anticipated launch of a new premium point-of-care hematology analyzer, Vetscan^® Opticell^™, in the second half of 2024. As the newest addition to the Diagnostics suite, it offers veterinary healthcare teams significant time, cost and space savings – leading to better patient outcomes and a more efficient clinic. The innovative AI-powered classification technology will offer a more advanced option for Complete Blood Count (CBC) analysis, providing lab-quality accuracy at the point-of-care.

In June, Zoetis published its 2023 Sustainability Report, highlighting specific actions the company has made by embedding sustainability across the business to support Communities, Animals and the Planet as it advances sustainability in animal health for a better future.

FINANCIAL GUIDANCE

Zoetis is raising its full year reported 2024 guidance due to the company's strong first half and the underlying strength in companion animal.

• Revenue between $9.100 billion to $9.250 billion (operational growth of 9% to 11%)
• Reported net income between $2.450 billion to $2.490 billion
• Adjusted net income between $2.640 billion to $2.690 billion (operational growth of 13.5% to 15.5%)
• Reported diluted EPS of $5.35 to $5.45
• Adjusted diluted EPS between $5.78 to $5.88

This guidance reflects foreign exchange rates as of late July. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning.

WEBCAST & CONFERENCE CALL DETAILS

Zoetis will host a webcast and conference call at 8:00 a.m. (ET) today, during which company executives will review second quarter 2024 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on August 6, 2024.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

¹ Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
² Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; expectations regarding timing and financial impact of divestitures; foreign exchange rates, tax rates and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.

Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.

ZTS-COR
ZTS-IR
ZTS-FIN

ZOETIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a)
(UNAUDITED)
(millions of dollars, except per share data)
	Three Months Ended										Six Months Ended
	June 30,										June 30,
		2024				2023			% Change			2024				2023			% Change
Revenue	$	2,361			$	2,180			8		$	4,551			$	4,180			9
Costs and expenses:
Cost of sales		668				607			10			1,311				1,195			10
Selling, general and administrative expenses		581				556			4			1,128				1,061			6
Research and development expenses		171				146			17			333				288			16
Amortization of intangible assets		35				37			(5)			72				74			(3)
Restructuring charges and certain acquisition and divestiture-related costs		42				8			*			46				29			59
Interest expense, net of capitalized interest		59				58			2			117				121			(3)
Other (income)/deductions–net		25				(104	)		*			17				(157	)		*
Income before provision for taxes on income		780				872			(11)			1,527				1,569			(3)
Provision for taxes on income		156				202			(23)			304				348			(13)
Net income before allocation to noncontrolling interests		624				670			(7)			1,223				1,221			—
Less: Net loss attributable to noncontrolling interests		—				(1	)		*			—				(2	)		*
Net income attributable to Zoetis Inc.	$	624			$	671			(7)		$	1,223			$	1,223			—
Earnings per share—basic	$	1.37			$	1.45			(6)		$	2.68			$	2.64			2
Earnings per share—diluted	$	1.37			$	1.45			(6)		$	2.67			$	2.64			1
Weighted-average shares used to calculate earnings per share
Basic		455.5				461.9						456.7				462.7
Diluted		456.0				462.9						457.4				463.8
(a) The condensed consolidated statements of income present the three and six months ended June 30, 2024 and 2023. Subsidiaries operating outside the United States are included for the three and six months ended May 31, 2024 and 2023.
* Calculation not meaningful.

ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
		Three Months Ended June 30, 2024
		GAAP Reported(a)				Purchase Accounting Adjustments				Acquisition and Divestiture- Related Costs(1)				Certain Significant Items(2)				Non-GAAP Adjusted(b)
Cost of sales		$	668			$	(1	)		$	—			$	—			$	667
Gross profit			1,693				1				—				—				1,694
Selling, general and administrative expenses			581				(3	)			—				—				578
Amortization of intangible assets			35				(31	)			—				—				4
Restructuring charges and certain acquisition and divestiture-related costs			42				—				(5	)			(37	)			—
Other (income)/deductions–net			25				—				—				(33	)			(8	)
Income before provision for taxes on income			780				35				5				70				890
Provision for taxes on income			156				8				1				14				179
Net income attributable to Zoetis			624				27				4				56				711
Earnings per common share attributable to Zoetis–diluted			1.37				0.06				0.01				0.12				1.56
		Three Months Ended June 30, 2023
		GAAP Reported(a)				Purchase Accounting Adjustments				Acquisition and Divestiture- Related Costs(1)				Certain Significant Items(2)				Non-GAAP Adjusted(b)
Cost of sales		$	607			$	(5	)		$	—			$	—			$	602
Gross profit			1,573				5				—				—				1,578
Selling, general and administrative expenses			556				(7	)			—				—				549
Amortization of intangible assets			37				(31	)			—				—				6
Restructuring charges and certain acquisition and divestiture-related costs			8				—				(4	)			(4	)			—
Other (income)/deductions–net			(104	)			—				—				94				(10	)
Income before provision for taxes on income			872				43				4				(90	)			829
Provision for taxes on income			202				9				1				(34	)			178
Net income attributable to Zoetis			671				34				3				(56	)			652
Earnings per common share attributable to Zoetis–diluted			1.45				0.07				0.01				(0.12	)			1.41
(a) The condensed consolidated statements of income present the three months ended June 30, 2024 and 2023. Subsidiaries operating outside the United States are included for the three months ended May 31, 2024 and 2023.
(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
		Six Months Ended June 30, 2024
		GAAP Reported(a)				Purchase Accounting Adjustments				Acquisition and Divestiture- Related Costs(1)				Certain Significant Items(2)				Non-GAAP Adjusted(b)
Cost of sales		$	1,311			$	(2	)		$	—			$	—			$	1,309
Gross profit			3,240				2				—				—				3,242
Selling, general and administrative expenses			1,128				(6	)			—				—				1,122
Research and development expenses			333				(1	)			—				—				332
Amortization of intangible assets			72				(63	)			—				—				9
Restructuring charges and certain acquisition and divestiture-related costs			46				—				(5	)			(41	)			—
Other (income)/deductions–net			17				—				—				(35	)			(18	)
Income before provision for taxes on income			1,527				72				5				76				1,680
Provision for taxes on income			304				16				1				14				335
Net income attributable to Zoetis			1,223				56				4				62				1,345
Earnings per common share attributable to Zoetis–diluted			2.67				0.12				0.01				0.14				2.94
		Six Months Ended June 30, 2023
		GAAP Reported(a)				Purchase Accounting Adjustments				Acquisition and Divestiture- Related Costs(1)				Certain Significant Items(2)				Non-GAAP Adjusted(b)
Cost of sales		$	1,195			$	(9	)		$	—			$	—			$	1,186
Gross profit			2,985				9				—				—				2,994
Selling, general and administrative expenses			1,061				(14	)			—				—				1,047
Amortization of intangible assets			74				(62	)			—				—				12
Restructuring charges and certain acquisition and divestiture-related costs			29				—				(5	)			(24	)			—
Other (income)/deductions–net			(157	)			—				—				92				(65	)
Income before provision for taxes on income			1,569				85				5				(68	)			1,591
Provision for taxes on income			348				17				1				(32	)			334
Net income attributable to Zoetis			1,223				68				4				(36	)			1,259
Earnings per common share attributable to Zoetis–diluted			2.64				0.14				0.01				(0.08	)			2.71
(a) The condensed consolidated statements of income present the six months ended June 30, 2024 and 2023. Subsidiaries operating outside the United States are included for the six months ended May 31, 2024 and 2023.
(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars)
(1)		Acquisition and divestiture-related costs include the following:
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2024			2023			2024			2023
		Acquisition-related costs(a)	$	1		$	3		$	1		$	4
		Divestiture-related costs(b)		4			—			4			—
		Restructuring charges(c)		—			1			—			1
		Total acquisition and divestiture-related costs—pre-tax		5			4			5			5
		Income taxes(d)		1			1			1			1
		Total acquisition and divestiture-related costs—net of tax	$	4		$	3		$	4		$	4
(a)		Acquisition-related costs represent external, incremental costs that directly relate to transacting and integrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b)		Divestiture-related costs represent external, incremental costs that directly relate to divesting and disintegrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.
(c)		Restructuring charges represent employee termination costs directly related to acquisitions and divestitures, included in Restructuring charges and certain acquisition and divestiture-related costs.
(d)		Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

(2)		Certain significant items include the following:
			Three Months Ended							Six Months Ended
			June 30,							June 30,
			2024			2023				2024			2023
		Other restructuring charges and cost-reduction/productivity initiatives(a)	$	37		$	4			$	41		$	24
		Certain asset impairment charges(b)		11			10				11			10
		Loss on assets held for sale(c)		22			—				22			—
		Net gain on sale of business(d)		—			(101	)			—			(101	)
		Other		—			(3	)			2			(1	)
		Total certain significant items—pre-tax		70			(90	)			76			(68	)
		Income taxes(e)		14			(34	)			14			(32	)
		Total certain significant items—net of tax	$	56		$	(56	)		$	62		$	(36	)
(a)		For the three and six months ended June 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, included in Restructuring charges and certain acquisition and divestiture-related costs. For the six months ended June 30, 2024, charges were partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
		For the three and six months ended June 30, 2023, primarily consisted of employee termination costs related to organizational structure refinements, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b)		For the three and six months ended June 30, 2024, represents certain asset impairment charges related to our aquaculture business included in Other (income)/deductions–net.
		For the three and six months ended June 30, 2023, represents certain asset impairment charges related to our precision animal health business, included in Other (income)/deductions–net.
(c)		Represents a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, included in Other (income)/deductions–net.
(d)		Represents a net gain on the sale of a majority interest in our pet insurance business, included in Other (income)/deductions–net.
(e)		Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. For the three and six months ended June 30, 2023, also includes tax expense related to changes to prior years' tax positions with regard to the one-time mandatory deemed repatriation tax under the Tax Cuts and Jobs Act.

ZOETIS INC.
ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)
(UNAUDITED)
(millions of dollars)
		Three Months Ended
		June 30,								% Change
			2024				2023			Total				Foreign Exchange			Operational(b)
Adjusted cost of sales		$	667			$	602			11	%			3	%		8	%
as a percent of revenue			28.3	%			27.6	%		NA				NA			NA
Adjusted SG&A expenses			578				549			5	%			(2	)%		7	%
Adjusted R&D expenses			171				146			17	%			—	%		17	%
Adjusted net income attributable to Zoetis			711				652			9	%			(9	)%		18	%

		Six Months Ended
		June 30,								% Change
		2024				2023				Total				Foreign Exchange			Operational(b)
Adjusted cost of sales		$	1,309			$	1,186			10	%			3	%		7	%
as a percent of revenue			28.8	%			28.4	%		NA				NA			NA
Adjusted SG&A expenses			1,122				1,047			7	%			(1	)%		8	%
Adjusted R&D expenses			332				288			15	%			—	%		15	%
Adjusted net income attributable to Zoetis			1,345				1,259			7	%			(10	)%		17	%
(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

ZOETIS INC.
2024 GUIDANCE
Selected Line Items (millions of dollars, except per share amounts)	Full Year 2024
Revenue	$9,100 to $9,250
Operational growth(a)	9% to 11%
Adjusted cost of sales as a percentage of revenue(b)	Approximately 29.3%
Adjusted SG&A expenses(b)	$2,225 to $2,290
Adjusted R&D expenses(b)	$660 to $670
Adjusted interest expense and other (income)/deductions-net(b)	Approximately $200
Effective tax rate on adjusted income(b)	20.0% to 20.5%
Adjusted diluted EPS(b)	$5.78 to $5.88
Adjusted net income(b)	$2,640 to $2,690
Operational growth(a)(c)	13.5% to 15.5%
Certain significant items and acquisition and divestiture-related costs(d)	$80 - $90
The guidance reflects foreign exchange rates as of late July 2024.

Reconciliations of 2024 reported guidance to 2024 adjusted guidance follows:
(millions of dollars, except per share amounts)	Reported	Certain significant items and acquisition and divestiture-related costs(d)	Purchase accounting	Adjusted(c)
Cost of sales as a percentage of revenue	~ 29.4%		~ (0.1%)	~ 29.3%
SG&A expenses	$2,236 to $2,301		~ $(11)	$2,225 to $2,290
R&D expenses	$662 to $672		~ $(2)	$660 to $670
Interest expense and other (income)/deductions-net	~ $220	~ $(20)		~ $200
Effective tax rate	20.0% to 20.5%			20.0% to 20.5%
Diluted EPS	$5.35 to $5.45	~ $0.19	~ $0.24	$5.78 to $5.88
Net income attributable to Zoetis	$2,450 to $2,490	$80 - $90	~ $110	$2,640 to $2,690
(a) Operational results (a non-GAAP financial measure) excludes the impact of foreign exchange.
(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational results to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition and divestiture-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.
(d) Primarily includes certain nonrecurring costs related to acquisitions, divestitures and other charges.

ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
		Three Months Ended
		June 30,						% Change
		2024			2023			Total				Foreign Exchange			Operational(b)
Revenue:
Companion Animal		$	1,649		$	1,489		11	%			(1	)%		12	%
Livestock			694			671		3	%			(6	)%		9	%
Contract Manufacturing & Human Health			18			20		(10	)%			(1	)%		(9	)%
Total Revenue		$	2,361		$	2,180		8	%			(3	)%		11	%
U.S.:
Companion Animal		$	1,080		$	959		13	%			—	%		13	%
Livestock			228			206		11	%			—	%		11	%
Total U.S. Revenue		$	1,308		$	1,165		12	%			—	%		12	%
International:
Companion Animal		$	569		$	530		7	%			(5	)%		12	%
Livestock			466			465		—	%			(8	)%		8	%
Total International Revenue		$	1,035		$	995		4	%			(6	)%		10	%
Companion Animal:
Dogs and Cats		$	1,581		$	1,424		11	%			(2	)%		13	%
Horses			68			65		5	%			(1	)%		6	%
Total Companion Animal Revenue		$	1,649		$	1,489		11	%			(1	)%		12	%
Livestock:
Cattle		$	350		$	329		6	%			(6	)%		12	%
Poultry			132			131		1	%			(6	)%		7	%
Swine			130			133		(2	)%			(7	)%		5	%
Fish			62			52		19	%			(1	)%		20	%
Sheep and other			20			26		(23	)%			(2	)%		(21	)%
Total Livestock Revenue		$	694		$	671		3	%			(6	)%		9	%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
		Six Months Ended
		June 30,						% Change
		2024			2023			Total				Foreign Exchange			Operational(b)
Revenue:
Companion Animal		$	3,099		$	2,714		14	%			(2	)%		16	%
Livestock			1,414			1,429		(1	)%			(5	)%		4	%
Contract Manufacturing & Human Health			38			37		3	%			—	%		3	%
Total Revenue		$	4,551		$	4,180		9	%			(3	)%		12	%
U.S.:
Companion Animal		$	1,978		$	1,680		18	%			—	%		18	%
Livestock			493			490		1	%			—	%		1	%
Total U.S. Revenue		$	2,471		$	2,170		14	%			—	%		14	%
International:
Companion Animal		$	1,121		$	1,034		8	%			(5	)%		13	%
Livestock			921			939		(2	)%			(7	)%		5	%
Total International Revenue		$	2,042		$	1,973		3	%			(6	)%		9	%
Companion Animal:
Dogs and Cats		$	2,965		$	2,577		15	%			(2	)%		17	%
Horses			134			137		(2	)%			(2	)%		—	%
Total Companion Animal Revenue		$	3,099		$	2,714		14	%			(2	)%		16	%
Livestock:
Cattle		$	741		$	728		2	%			(4	)%		6	%
Poultry			271			270		—	%			(7	)%		7	%
Swine			257			275		(7	)%			(6	)%		(1	)%
Fish			107			101		6	%			(1	)%		7	%
Sheep and other			38			55		(31	)%			(4	)%		(27	)%
Total Livestock Revenue		$	1,414		$	1,429		(1	)%			(5	)%		4	%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

ZOETIS INC.
CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS
(UNAUDITED)
(millions of dollars)
		Three Months Ended
		June 30,						% Change
		2024			2023			Total				Foreign Exchange			Operational(a)
Total International		$	1,035		$	995		4	%			(6	)%		10	%
Australia			83			82		1	%			(1	)%		2	%
Brazil			99			91		9	%			(1	)%		10	%
Canada			75			70		7	%			(1	)%		8	%
Chile			31			39		(21	)%			(4	)%		(17	)%
China			68			84		(19	)%			(3	)%		(16	)%
France			34			34		—	%			(2	)%		2	%
Germany			58			53		9	%			(1	)%		10	%
Italy			36			35		3	%			1	%		2	%
Japan			39			47		(17	)%			(13	)%		(4	)%
Mexico			46			38		21	%			11	%		10	%
Spain			33			31		6	%			(2	)%		8	%
United Kingdom			73			63		16	%			3	%		13	%
Other developed markets			138			125		10	%			(2	)%		12	%
Other emerging markets			222			203		9	%			(25	)%		34	%

		Six Months Ended
		June 30,						% Change
		2024			2023			Total				Foreign Exchange			Operational(a)
Total International		$	2,042		$	1,973		3	%			(6	)%		9	%
Australia			156			164		(5	)%			(3	)%		(2	)%
Brazil			200			175		14	%			3	%		11	%
Canada			136			120		13	%			(1	)%		14	%
Chile			62			78		(21	)%			(4	)%		(17	)%
China			144			186		(23	)%			(3	)%		(20	)%
France			75			68		10	%			(1	)%		11	%
Germany			109			98		11	%			—	%		11	%
Italy			64			61		5	%			1	%		4	%
Japan			76			86		(12	)%			(12	)%		—	%
Mexico			90			77		17	%			11	%		6	%
Spain			65			64		2	%			—	%		2	%
United Kingdom			150			131		15	%			4	%		11	%
Other developed markets			265			247		7	%			(1	)%		8	%
Other emerging markets			450			418		8	%			(25	)%		33	%
(a) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
		Three Months Ended
		June 30,								% Change
			2024				2023			Total				Foreign Exchange			Operational(b)
U.S.:
Revenue		$	1,308			$	1,165			12	%			—	%		12	%
Cost of Sales			232				214			8	%			—	%		8	%
Gross Profit			1,076				951			13	%			—	%		13	%
Gross Margin			82.3	%			81.6	%
Operating Expenses			204				212			(4	)%			—	%		(4	)%
Other (income)/deductions-net			—				—			*				*			*
U.S. Earnings		$	872			$	739			18	%			—	%		18	%
International:
Revenue		$	1,035			$	995			4	%			(6	)%		10	%
Cost of Sales			342				315			9	%			—	%		9	%
Gross Profit			693				680			2	%			(9	)%		11	%
Gross Margin			67.0	%			68.3	%
Operating Expenses			175				166			5	%			(4	)%		9	%
Other (income)/deductions-net			—				(1	)		*				*			*
International Earnings		$	518			$	515			1	%			(10	)%		11	%
Total Reportable Segments		$	1,390			$	1,254			11	%			(4	)%		15	%
Other business activities(c)			(142	)			(116	)		22	%
Reconciling Items:
Corporate(d)			(299	)			(256	)		17	%
Purchase accounting adjustments(e)			(35	)			(43	)		(19	)%
Acquisition and divestiture-related costs(f)			(5	)			(4	)		25	%
Certain significant items(g)			(70	)			90			*
Other unallocated(h)			(59	)			(53	)		11	%
Total Earnings(i)		$	780			$	872			(11	)%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, as well as a loss on assets held for sale and the impact of divestiture gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
* Calculation not meaningful.

ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
		Six Months Ended
		June 30,								% Change
			2024				2023			Total				Foreign Exchange			Operational(b)
U.S.:
Revenue		$	2,471			$	2,170			14	%			—	%		14	%
Cost of Sales			449				417			8	%			—	%		8	%
Gross Profit			2,022				1,753			15	%			—	%		15	%
Gross Margin			81.8	%			80.8	%
Operating Expenses			394				400			(2	)%			—	%		(2	)%
Other (income)/deductions-net			—				—			*				*			*
U.S. Earnings		$	1,628			$	1,353			20	%			—	%		20	%
International:
Revenue		$	2,042			$	1,973			3	%			(6	)%		9	%
Cost of Sales			655				606			8	%			—	%		8	%
Gross Profit			1,387				1,367			1	%			(9	)%		10	%
Gross Margin			67.9	%			69.3	%
Operating Expenses			334				317			5	%			(4	)%		9	%
Other (income)/deductions-net			—				—			*				*			*
International Earnings		$	1,053			$	1,050			—	%			(10	)%		10	%
Total Reportable Segments		$	2,681			$	2,403			12	%			(4	)%		16	%
Other business activities(c)			(274	)			(230	)		19	%
Reconciling Items:
Corporate(d)			(587	)			(464	)		27	%
Purchase accounting adjustments(e)			(72	)			(85	)		(15	)%
Acquisition and divestiture-related costs(f)			(5	)			(5	)		—	%
Certain significant items(g)			(76	)			68			*
Other unallocated(h)			(140	)			(118	)		19	%
Total Earnings(i)		$	1,527			$	1,569			(3	)%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, as well as a loss on assets held for sale and the impact of divestiture gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
* Calculation not meaningful.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240805847620/en/

Media Contacts:

Jennifer Albano

1-862-399-0810 (o)

jennifer.albano@zoetis.com

Laura Panza

1-973-975-5176 (o)

laura.panza@zoetis.com

Investor Contacts:

Steve Frank

1-973-822-7141 (o)

steve.frank@zoetis.com

Nick Soonthornchai

1-973-443-2792 (o)

nick.soonthornchai@zoetis.com

Source: Zoetis Inc.

FAQ

What was Zoetis (ZTS) revenue in Q2 2024?

Zoetis reported revenue of $2.4 billion in Q2 2024, representing an 8% increase compared to Q2 2023.

How did Zoetis (ZTS) perform in the U.S. market in Q2 2024?

Zoetis' U.S. segment revenue increased by 12% in Q2 2024, with companion animal products growing by 13% and livestock products by 11%.

What is Zoetis (ZTS) full-year revenue guidance for 2024?

Zoetis raised its full-year 2024 revenue guidance to between $9.100 billion and $9.250 billion, representing 9% to 11% operational growth.

Which products drove Zoetis (ZTS) growth in Q2 2024?

Key growth drivers included osteoarthritis pain products Librela and Solensia, flea and tick product Simparica Trio, and dermatology offerings Apoquel and Cytopoint.